ERCC8-related disorders are more commonly known as Cockayne syndrome type A, an inherited disorder characterized by severe growth delay, a small head size, developmental delays, and intellectual disabilities. Other common features of the condition include an increased sensitivity to sunlight (photosensitivity), significant tooth decay, vision problems, and hearing loss. In addition, affected individuals may have certain facial features such a small chin, large ears, and a slender nose, which may make them appear older than their actual age.
ERCC8-related disorders are sometimes divided into three forms called Cockayne syndrome type I, Cockayne syndrome type II, and Cockayne syndrome type III. These forms differ in the age at which symptoms first appear and how fast the symptoms progress. However, the three forms are not completely distinct, with some patients having features consistent with more than one type.
Cockayne syndrome type I is the most common type of ERCC8-related disorder. Newborns with this type generally appear normal. However, their growth slows considerably within the first two years of life. With time, their length, weight, and head size are all significantly less than expected for their age. Affected children also develop vision and hearing problems that worsen over time, as well as neurological problems such as increased muscle tone, difficulty walking, tremors, seizures, feeding difficulties, and behavioral issues. Other possible symptoms include (but are not limited to) cataracts, frequent cavities, dry skin and hair, bone problems, and changes in the brain that can be seen on brain imaging.
Cockayne syndrome type II (sometimes called cerebro-oculo-facio-skeletal [COFS] syndrome or Pena-Shokeir syndrome type II) is the most severe form of the disease, with signs and symptoms appearing at birth or in the newborn period. Infants are small at birth and often have cataracts or other eye abnormalities (such as small corneas). With time, they continue to have significant problems with growth and severe developmental delays. Affected children are typically unable to speak and cannot sit or walk independently.
Cockayne syndrome type III is the mildest form of the condition, with symptoms appearing later in childhood. While affected children with this type have some of the features associated with Cockayne syndrome types I and II, their growth deficiency and developmental delays are not as severe.
It has been estimated that Cockayne syndrome affects approximately 1 in 200,000 Europeans each year. ERCC8 accounts for 35% of individuals affected with Cockayne syndrome. Studies have also suggested that the condition may be more common in certain populations in Northern Israel.
There is no cure for ERCC8-related disorders. Treatment is focused on managing the symptoms of the condition. This may include medication for muscle stiffness, tremors, or seizures, physical therapy and assistive devices for mobility issues, educational programs for intellectual disabilities, feeding tubes for those with significant feeding difficulties, hearing aids for those with hearing loss, and standard therapies for the treatment of cataracts or other vision problems. In addition, aggressive dental care will help minimize the risk of cavities and sun protection is necessary for managing photosensitivity, although exposure to excessive sunlight should be avoided. Metronidazole (a type of antibiotic) should also be avoided, as use of this medication can cause liver failure in individuals with Cockayne syndrome.
The prognosis for ERCC8-related disorders varies depending on the type of Cockayne syndrome. Most individuals with Cockayne syndrome type I die by the age of 20, with an average age at death of 12 years. However, survival past the age of 20 has been reported. For those with Cockayne syndrome type II, the most severe form of the condition, death by the age of 7 is typical. The average life expectancy for those with Cockayne syndrome type III is not currently known.
The mission of this organization is to help children with Cockayne syndrome and their families improve quality of life through support, education, and research.
Share and Care
P.O. Box 282
Waterford, VA 20197
A medical database of genetic disorders funded by the National Institutes of Health and developed at the University of Washington, Seattle. Much of the language in GeneReviews is geared toward physicians and other scientists.
Explanations of an extensive number of genetic diseases written by the U.S. government's National Institutes of Health.
Counsyl has renamed its products effective July 19, 2017. The Family Prep Screen is now the Foresight Carrier Screen.
The new names now appear on all communications from Counsyl. If you have any questions, please contact Counsyl directly.